Skip to Content

AC-170 Approval Status

  • FDA approved: No
  • Brand name: AC-170
  • Generic name: cetirizine
  • Company: Nicox S.A.
  • Treatment for: Conjunctivitis, Allergic

AC-170 (cetirizine) is a second generation antihistamine topical ophthalmic formulation in development for the treatment of ocular itching associated with allergic conjunctivitis.

On October 10 2016, Nicox S.A. announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for AC-170. The FDA’s stated reason for the CRL pertains solely to a Good Manufacturing Practice (GMP) inspection at the third party facility producing cetirizine, the active pharmaceutical ingredient in AC-170.

Development Status and FDA Approval Process for AC-170

Oct 10, 2016Nicox Receives Complete Response Letter from the FDA Related to GMP on NDA for AC-170
Jun 21, 2016U.S. FDA grants Priority Review for Nicox’s AC-170 New Drug Application
Apr 19, 2016Nicox submits New Drug Application for AC-170 to U.S. FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.